Please use this identifier to cite or link to this item:
|Title:||225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer|
|Authors:||SATHEKGE MIKE; BRUCHERTSEIFER FRANK; KNOESEN OTTO; REYNEKE F; LENGANA T; LAWAL I; BOSHOMANE T; MOKOALA K; VORSTER MARIZA; MORGENSTERN ALFRED|
|Citation:||JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES vol. 50 no. 1 p. S30|
|Type:||Articles in periodicals and books|
|Abstract:||225Ac- Prostate-specific membrane antigen (PSMA)-617 is a highly promising novel compound for therapy of prostate cancer. A remarkable therapeutic efficacy has been demonstrated in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients, with xerostomia as the main side effect. A promising strategy for minimization of side effects is based on optimization of the dosing regime while maintaining sufficient therapeutic efficacy for several cohorts of patients, including chemotherapy-naïve patients.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.